Cellerix

Madrid, 10th March 2008.— Cellerix, a biopharmaceutical company that develops and produces innovative medicines based on cell therapy, has appointed Claudia Jimenez as Director of Business Development of its management team.

Claudia Jimenez has two degrees in International Business, one from the Universidad Pontificia Comillas (ICADE) of Spain and the other from FDH Reutlingen (Germany). In addition, she holds an international MBA from the Instituto de Empresa in Madrid.

She began her career in investment banking at WestLB Panmure (Germany), where she held several different jobs during her five-year tenure, the last one in the mergers & acquisitions department, where she was in charge of projects for several different industries, including pharmaceuticals and biotechnology. Before joining Cellerix, she was employed for two years at Genetrix as the Director of Business Development, where she led projects for Cellerix, including the agreement with Axcan Pharma.

In her new job, Claudia Jimenez will be responsible for the product licensing activities at Cellerix and for identifying and evaluating new growth opportunities through licensing, collaboration agreements and strategic alliances or M&A activities. Lastly, she will be in charge of coordinating all these projects.

Notes to editors

Cellerix is a biopharmaceutical company developing innovative medicines based on cell therapy. The company has two products undergoing clinical trials: Cx401 for the treatment of perianal fistulas, currently in Phase III, and Cx501 for skin regeneration, currently in Phase II. Cx401 and Cx501 have orphan status by the European Medicines Agency (EMEA). Cellerix closed in September 2007 a €27.2 million financing round led by international venture capital companies. In October 2007 it entered into an exclusive license and development agreement with Axcan Pharma for the North American rights to Cx401.